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Oral  OXY  – better  post-caesarean  section  pain  control  vs.  nurse-administered  i.v.  morphine/oral  codeine.
Oral  OXY  – less  opioid  consumption  with  oxycodone  vs.  i.v. morphine/oral  codeine.
Oral  OXY  –  less  time  consuming  than  giving  i.v.  morphine  during  the  ﬁrst  24  h.
Both  treatment  protocols  are  safe  for  both  the mother  and the  newborn.
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Background  and  aims:  The  present  randomized  open  label  parallel  group  study  was  conducted  to eval-
uate  if an  oral  oxycodone  (OXY)  regimen  can be at least  equally  effective  and as safe  for postoperative
analgesia  after  caesarean  section  (CS)  as  a standard  of  care  program  using nurse-administered  intravenous
morphine  (IVM),  followed  by  oral  codeine.
Methods:  Eighty  women  (40  +  40)  were  scheduled  for elective  CS  under  spinal  anaesthesia.  All patients
received  postoperative  multimodal  analgesic  therapy,  including  ibuprofen  and  paracetamol.  The  OXY
group  got  standardized  extended  release  and  short  acting  oral  treatment  (and  in  a  few  cases  intravenous
OXY)  as  needed  and the  other  group  received  current  standard  of  care,  IVM  as  needed  for 24  h,  followed  by
codeine.  Opioid  treatment  lasted  maximum  ﬁve  days.  Outcome  measures  were  pain  intensity  (numer-
ical rating  scale,  NRS),  opioid  requirements,  duration  of  administering  opioids  and  safety  for  mother
and  newborn.  All  opioids  in the study  were  expressed  in  OXY  equivalents,  using  a  conversion  table.  As
the bioavailability  of  each  opioid  has a certain  extent  of  interindividual  bioavailability  this  conversion
represents  an approximation.  The  possible  inﬂuence  of opioids  on  the newborns  was evaluated  by the
Neurological  Adaptive  Capacity  Score  at birth  and  at 24  and  48 h.
Results:  During  the  ﬁrst  24 h, there  were  no differences  between  treatments  in  opioid requirements
or  mean  pain  intensity  at rest  but pain  intensity  when  asking  for rescue  medication  was  lower  in the
OXY  than  in  the IVM  group  (mean  ±  SD; 5.41  ± 6.42  vs. 6.42 ± 1.61;  p  = 0.027).  Provoked  pain  (uterus
palpation)  during  the  ﬁrst 6  h was  also less  in  the  OXY  group  (3.26  ± 2.13  vs. 4.60  ±  2.10;  p =  0.007).
During  the  25–48  h period  postoperatively,  patients  on OXY  reported  signiﬁcantly  lower  pain  intensity
at  rest  (2.9 ± 1.9  vs. 3.8  ± 1.8;  p =  0.039)  and  consumed  less  opioids  (OXY  equivalents;  mg) (31.5  ± 9.6
vs.  38.2  ± 38.2;  p = 0.001)  than  those  on  IVM/codeine.  The  total  amount  of  opioids  0–5  days  postopera-
tively  was signiﬁcantly  lower  in the  OXY  than  in  the IVM/codeine  group  (108.7  ±  37.6 vs. 138.2  ±  45.1;
p  =  0.002).  Duration  of  administering  opioids  was  signiﬁcantly  shorter  in  the OXY  group.  Time  to ﬁrst
spontaneous  bowel  movement  was  shorter  in  the  OXY  group  compared  with  the  IVM/codeine  group.  No
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serious  adverse  events  were  recorded  in the  mothers  but  the  total  number  of  common  opioid  adverse
effects  was  higher  among  women  on IVM/codeine  than among  those  receiving  OXY  (15 vs.  3;  p =  0.007).
No adverse  outcomes  in the  newborns  related  to treatment  were  observed  in  either  group.
Conclusions:  In  a  multimodal  protocol  for postoperative  analgesia  after  CS  better  pain  control  and  lower
opioid  intake  was  observed  in  patients  receiving  oral OXY  as compared  to those  on IVM/codeine.  No  safety
risks for  mother  and child  were  identiﬁed  with  either  protocol.
Implications:  Our  ﬁndings  support  the  view  that  use  of oral  OXY  is  a simple,  effective  and  time  saving
treatment  for  postoperative  pain  after  CS.
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. Introduction
Postoperative pain treatment in women undergoing caesarean
ection (CS) needs to be effective to enable fast and smooth recov-
ry without adverse outcomes and to improve breastfeeding and
onding between mother and child. It is also important that pain
reatment should have minimal impact on the newborn [1].
In spite of this, ineffective postoperative pain treatment regi-
ens are common [2,3]. There is a lack of guidelines for post
aesarean pain management, not only in Sweden but also in many
ther countries, even though neuraxial blockade in combination
ith non-opioids has been suggested as golden standard [3,4].
atient controlled analgesia (PCA) with morphine has also been
sed for postoperative pain control [5]. However, i.v. administra-
ion of morphine to women after CS is mostly used for a short period
f time and the PCA-device itself might cause some practical incon-
enience for the mother. Also weak opioids are still commonplace
n the prolonged postoperative period, codeine + paracetamol often
eing the standard of care after surgeries [6]. Multimodal postop-
rative pain treatment has been shown to be more effective than
onotherapy [7,8]. Many advantages can be identiﬁed with oral
edication, including simplicity, time saving vs. i.v. medication and
akes the patient more independent [9].
Overall, oral low-tech treatment regimens are preferred, both by
atients and ward staff, but they need to be efﬁcient with a good
afety proﬁle and allow for patients to ambulate freely.
The precursor drug codeine may  be problematic to rely on for
fﬁcacy. The analgesic effect of codeine is attributed to the indi-
iduals’ ability to convert codeine to morphine via CYP2D6. The
YP2D6 genotype has three important phenotypes: rapid (normal),
low and ultrarapid metabolizers. The latter will have a markedly
igher exposure to morphine [10,11]. The genetic predisposition
or either phenotype has considerable variability due to ethnicity,
hich makes standardization of treatment regimens challenging in
 mixed ethnic population.
Recent case reports address neonatal safety concerns, includ-
ng death, when the mother has been taking codeine for a
rolonged period of time [12,13]. Using oral morphine instead
f codeine would reduce inter-individual variation in exposure.
nother option is to use oral oxycodone, which has a higher
nd more predictable oral bioavailability (67–80%) than morphine
19–47%) [14,15]. Substituting codeine with oral OXY can there-
ore be expected to further reduce the variation in bioavailability
nd analgesic effect [15,16]. Seaton et al. studied to what extent
XY passes into breast milk, but only a few variables concerning
he child were reported [17]. The standard multimodal treatment
ollowing CS in our department has included intravenous (i.v.) mor-
hine (IVM), which after 24 h was substituted by oral codeine.
he ethnic composition of patients in our department includes
roups with high prevalence of slow metabolizers as well as groups
ith high prevalence of ultra-rapid metabolizers, which puts high
emands on a standard of care that is safe and efﬁcient for all.
e hypothesized that a standardized multimodal postoperative
nalgesic regimen for the ﬁrst ﬁve postoperative days includinghed  by Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/4.0/).
a potent opioid, OXY, would be at least as effective with regard to
pain and total opioid requirement as IVM/oral codeine when given
as adjunct to paracetamol + ibuprofen. Further, we hypothesized
that this regimen would improve patient overall satisfaction with-
out jeopardizing maternal or neonatal safety in terms of recognized
opioid related adverse effects.
2. Materials and methods
The present randomized open parallel group study in women
undergoing planned CS was  approved by the Regional Ethics Com-
mittee in Stockholm, Sweden (2010/1062-31/1) Swedish Medical
Products Agency (151:2010/42559) and Eudra-CT (2010-018450).
Healthy women, 18–50 years old, planned for CS from 38 full
weeks of gestation, having the intention to breastfeed and who
had sufﬁcient understanding of the Swedish language, were eligi-
ble for inclusion. Exclusion criteria included: ongoing participation
in another clinical trial, treatment for chronic pain, drug abuse,
mental illness, patients treated with antidepressants, known intol-
erance or allergy towards any of the study drugs, maternal disease
that could affect pregnancy and foetal complications e.g. large
for gestational age or intrauterine growth retardation. Eighty
healthy women who  met  the inclusion criteria were recruited
from November 2010 to August 2012 at Karolinska University
Hospital, Sweden. After obtaining verbal and written informed con-
sent patients were randomized using a computer-based program,
in blocks of twenty. Each randomization number had a corre-
sponding sealed-opaque envelope, containing study treatment
information. Envelopes for each patient were drawn sequentially
from a sealed box. The designated envelope was  opened the day
before CS by one of the investigators. The correct medication
was prepared and ordained in the patient’s records. An open
label design was chosen for ethical reasons, since we also col-
lected samples for analyses of OXY exposure but chose not to do
so for morphine/codeine. A timeline describes the study design
(Fig. 1).
2.1. Study treatment
2.1.1. Treatment common for both groups
One hour preoperatively patients received 2 g oral paracetamol
(Alvedon®, AstraZeneca, Sweden) as a bolus dose according to local
routines. Spinal anaesthesia was  administered using 1.8–2.6 ml
(body height depending) bupivacaine (Marcain Tung® 5 mg/ml,
AstraZeneca, Sweden) plus 15 g (0.3 ml)  fentanyl (Fentanyl®
50 g/ml, Meda AB, Sweden) through a 27 G Sproutte spinal needle
at L2–L3 or L3–L4 with the woman in sitting position. Immedi-
ately after surgery, before leaving the operating room, all patients
received oral ibuprofen 400 mg  (Brufen®, Abbott Laboratories,
Sweden). During the rest of the hospital stay, and longer if needed,
all patients continuously received 200 mg  ibuprofen every 6 h. Oral
parafﬁn emulsion (30 ml)  was given twice daily to diminish consti-
pation.
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Fig. 1
.1.2. Postoperative treatment – oxycodone group
Before leaving the operating room, women received 20 mg
ong acting OXY (OxyContin®, Mundipharma, Sweden). Thereafter,
0 mg  OxyContin® was given every 12 h for minimum 48 h. Rescue
edication was given as an oral dose of 5 mg  immediate release
XY (OxyNorm®, Mundipharma, Sweden). In the case of severe
reakthrough pain, 1–5 mg  of i.v. OXY (OxyNorm®, Mundipharma,
weden); 10 mg/ml, 1 ml  diluted with 9 ml  saline solution (Natri-
mklorid 9 mg/ml, Fresenius, Sweden) were given. Occasionally,
hort acting OXY was given before mobilization. All patients in
his group received 1 g oral paracetamol every 6 h until discharged,
onger if needed.
.1.3. Postoperative treatment – intravenous morphine/codeine
roup
For 24 h, morphine (Morﬁn MEDA® 10 mg/ml, MEDA, Sweden),
iluted in saline (Natriumklorid 9 mg/ml, Fresenius, Sweden)
as nurse-administered by slow i.v. injection until an adequate
esponse, NRS < 4/10, was obtained (if more than 10 mg  the
esponsible physician was contacted). After 24 h, morphine and
aracetamol were substituted by a combination treatment of
aracetamol 500 mg  plus codeine 30 mg  (Citodon®, BioPhausia,
weden), two tablets every 6 h for up to at least 48 h.
.1.4. Postoperative days three to ﬁve
Upon discharge, approximately 48 h postoperatively, women
eceived oral analgesics for up to ﬁve days postoperatively. Women
n the OXY group received 10 mg  OxyContin®, six tablets, to take
s needed, twice daily. Women  in the IVM/codeine group receivedparacetamol and  ibuprof en 
line.
Citodon®, maximum dose eight tablets per day. All patients were
recommended to continue with paracetamol/ibuprofen when opi-
oids were no longer required. In the IVM/codeine group, Citodon®
was replaced by paracetamol.
2.2. Pain assessments
Patients reported their present pain intensity on a Numerical
Rating Scale (NRS) (0–10, where 0 depicts “no pain” and 10 “worst
pain imaginable”). Pain at rest was  assessed every hour for 6 h and
thereafter once every working shift (morning, afternoon and night)
during the hospital stay. Provoked pain (during uterus palpation
performed by the responsible midwife) was  evaluated 6 times dur-
ing 0–24 h postoperatively. Further, pain was assessed at request
for rescue medication (maximum pain).
2.3. Mobilization
Three steps of postoperative mobilization were recorded:
the woman  standing next to the bed, walking in the room
for the ﬁrst time and being fully mobilized, i.e. back to
circumstantially normal activities. Women received additional
medication before mobilization if needed. Early mobilization was
encouraged.2.4. Opioid requirements
Opioid consumption was  recorded and accumulated for 0–24
and 25–48 h as well as for the whole 5-day postoperative period.
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Table 1
Conversion rates for opioids used in the present clinical trial.
Drug Parenteral (mg) Oral (mg)
Codeine NA 200
Morphine 10 30
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Mean pain at rest was signiﬁcantly lower in the OXY group
at 0–6 h, 25–48 h and when asking for rescue medication 0–24 h.
When evaluating the whole 0–24 h period no signiﬁcant difference
Table 2
Demographics.
Demographic OXY group
n = 38
IVM/codeine group
n  = 39
Age (years), median (range) 33.5 (23–42) 34.0 (21–44)
Gravida median (range) 2.5 (1–6) 3 (1–6)
Parity median (range) 1 (0–4) 1 (0–3)
Primiparas n = 11 n = 8
Multiparas n = 27 n = 31
Previous caesarean section,
median (range)
0.5 (1–4)
n = 19
0.5 (1–3)
n = 22
Previous abdominal surgery
(including CS), median
(range)
1 (1–4)
n = 19
1 (1–4)
n  = 25
Body mass index (BMI),
median (range)
29.5
(22.3–43.7)
29.0
(24.2–52.5)
Educationa
Compulsory school n = 1 n = 1
Senior high school n = 11 n = 17Oxycodone 10 20
dapted according to McPherson [18].
ll opioids were converted to oral OXY equivalents according to
able 1 [18].
.5. Safety variables
Side effects of opioid exposure in the mothers were recorded
ased on spontaneous reporting and open questions. Signs of sur-
ical site infections (SSI) were recorded and treated according to
linical routines. In the newborns, birth weight and weight devel-
pment were recorded. At delivery, Apgar scores at 1, 5 and 10 min
ere recorded and umbilical cord blood was collected for acid–base
nalyses. All newborns were evaluated by one of the two  authors
BN or CA) familiar with the Neurological and Adaptive Capacity
core (NACS) method [19]. The ﬁrst evaluation, 30 min  after deliv-
ry, was used as baseline. NACS was then assessed 24 and 48 h
ostpartum, to detect possible neurological symptoms due to opi-
id exposure. NACS is based on 20 criteria in ﬁve general areas:
daptive capacity, active and passive tone, primary reﬂexes and
eneral observations (motor activity, alertness and crying). Each
tem is scored as 0, 1 or 2, adding up to a maximal total score of
0. Scores ≥35 indicates a healthy newborn. Other variables, e.g.
ncreased bilirubin outside the normal range, need for additional
eeding and admission to the neonatal intensive care unit (NICU)
ere also recorded.
Maternal serum and breast milk samples for analysis of OXY
nd its metabolites were collected at 24 (±4) and 48 (±4) h post-
peratively. Serum samples from the newborns were taken only at
8 (±4) h, when samples for routine neonatal screening were also
ecured. These data will be published elsewhere.
.6. Follow-up
On the day of discharge, all women completed a questionnaire
oncerning their pain experience. Questions related to satisfaction
ith pain relief, staffs acceptance of analgesic requirement, under-
tanding of instructions regarding pain treatment and, if applicable,
heir postoperative pain compared to previous CS.
On postoperative day ﬁve, one of the investigators (BN or CA)
ontacted the women via telephone to determine opioid con-
umption since discharge. Ten days postoperatively a structured
ollow-up telephone interview was performed. Women  were asked
f they still experienced pain and in this case the location and type
f pain. They were asked when they ended intake or if they still
equired analgesics. Questions also included pain interference with
aily life, general postoperative recovery, perception of undergoing
 CS and of the general care received.
.7. Collection of data
Demographics and medical data, except pharmaceutical
ecords, were collected from the computer based patient record
ystem ObstetrixTM (Siemens, Sweden). Data concerning admin-
stration of drugs were secured from the computer based patient
hart system Take CareTM (CompuGroup Medical, Sweden). The pri-
ary data collected were: woman’s age, weight and body mass
ndex (BMI) at the time of surgery, indication for CS, parity and anyurnal of Pain 7 (2015) 17–24
previous CS. All data were codiﬁed and made anonymous before
data entry.
2.8. Nursing aspects
All midwives in the maternity ward recorded the time spent
administering analgesics (from time of request, preparing and
administering the drug and evaluating the effect). The number of
occasions when patients required supplementary pain relief and
total time spent were recorded.
2.9. Statistical analysis
The primary outcome variable was  pain at rest during the 48 h
postoperative period. Main secondary variable was total opioid
requirements during days 0–5. Other secondary variables were
number of requests for rescue medication, pain upon request for
rescue medication, time to mobilization, patient satisfaction and
time to ﬁrst defecation. Exploratory variables included time to
administer analgesics and midwife global impression. Neonate
safety variables included NACS, weight development and any
aberrant observations regarding the newborns. Maternal safety
variables included SSI and spontaneous report and open questions
regarding any adverse effects.
The statistics software IBM PASW Statistics, version 18.0, was
used to analyse differences between groups. Two-tailed Student’s
t-test was used when comparing NRS, opioid consumption and
safety variables. For demographic data, interviews and question-
naires the Pearson’s Chi-Square test was used. A level of p ≤ 0.05
was considered signiﬁcant.
3. Results
Eighty patients were randomized and three patients were with-
drawn before study treatment due to failed spinal block, two  in the
OXY group and one in the IVM/codeine group (Fig. 2). There were no
signiﬁcant differences between groups in demographic parameters
(Table 2).
3.1. Pain intensityUniversity n = 23 n = 20
Postgraduate n = 2 n = 1
Missing n = 1 n = 0
a Based on information collected at time of ﬁrst (antenatal) interview.
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Table 3
Pain (NRS) at rest, maximum pain, provoked pain and number of rescue medications.
Variable OXY group
n = 38
IVM/codeine group
n  = 39
p value
Pain at rest
0–6 h 3.80 ± 1.52 4.96 ± 1.49 0.002
0–24  h 3.43 ± 1.74 3.93 ± 1.30 n.s.
25–48  h 2.89 ± 1.88 3.80 ± 1.83 0.039
Provoked pain (uterus palpation)
0–6 h 3.26 ± 2.13 4.60 ± 2.10 0.007
0–24  h 5.98 ± 2.13 6.62 ± 2.02 n.s.
Maximum pain intensity (when asking for rescue medication)
0–24 h 5.41 ± 2.17 6.42 ± 1.61 0.027Fig. 2.
etween groups was observed. Provoked pain (uterus palpation)
as signiﬁcantly less in the OXY group during the ﬁrst 6 h (Table 3).
.2. Opioid requirements
There were no signiﬁcant differences in opioid consumption
uring the ﬁrst 24 h postoperatively. However, during the 25–48 h
eriod and from 49 h until 5 days postoperatively there was sig-
iﬁcantly less opioid consumption in the OXY group than in the
VM/codeine group (Table 4). The need for rescue medication
uring the ﬁrst 24 h was less frequent in the OXY than in the
VM/codeine group (Table 3). As a standardized conversion table
as used for opioid calculations these data to some extent repre-
ent an approximation..3. Postoperative recovery
There was no difference in mobilization between groups.
omen  in the OXY group had a signiﬁcantly shorter time period
ntil ﬁrst bowel movement (Table 5).Number of rescue medications
0–24 h 4.3 ± 3.6 8.4 ± 11.7 0.047
All data are shown as mean ± SD (Student’s t-test, p ≤ 0.05 was considered signiﬁ-
cant).
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Table 4
Amount of opioids in oxycodone equivalents (mg).
OXY groupn = 38 IVM/codeine groupn = 39 p value
0–24 h 49.5 ± 20.1 45.4 ± 24.2 n.s.
25–48 h 31.5 ± 9.6 38.2 ± 11.6 0.001
49  h–5 days 27.7 ± 15.5 54.7 ± 26.1 0.001
0–5  days 108.7 ± 37.6 138.2 ± 45.1 0.002
All data are shown as mean ± SD (Student’s t-test, p ≤ 0.05 was  considered signiﬁ-
cant).
Table 5
Variables related to postoperative mobilization.
Variable OXY group
n = 38
IVM/codeine
group
n = 39
p value
Stand next to the
bed (h)
9.6 ± 4.9 (4–25) 11.9 ± 6.2 (5–26.5) n.s
Walking around
with help (h)
16.8 ± 9.1 (5–47) 20.1 ± 8.4 (5–44) n.s.
Fully mobilized (h) 24.3 ± 11.4 (5–53) 30.6 ± 17.7 (5–67) n.s.
First bowel
movement
(postop day)
2.9 ± 1.4 (1–7) 3.6 ± 1.2 (1–6) 0.038
Discharge from
hospital (postop
day)
2.4 ± 0.6 (2–3) 2.4 ± 0.6 (2–5) n.s.
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Table 6
Telephone interview 10 days postoperatively.
Variable OXY group
(n = 38)
IVM/codeine group
(n  = 39)
p value
Wellbeing
Very good/good 38 (100%) 35 (87%) n.s.
Less  good/bad 0 4 (13%)
Scar pain
Yes 3 (8%) 7 (18%) n.s.
No  23 (60%) 19 (49%)
Only when moving 12 (32%) 13 (33%)
Still on pain medication
Yes 13 (34%) 14 (36%) n.s.
No  18 (48%) 15 (38%)
Only occasionally 7 (18%) 10 (26%)
Has pain been an obstacle in your everyday life
Yes 8 (21%) 19 (49%) 0.011
No  30 (79%) 20 (51%)
Has pain eased in expected time
Yes/much faster 36 (95%) 35 (90%) n.s.
No  2 (5%) 4 (10%)
Rate your perception of the hospital stay
Very
positive/positive
37  (97%) 36 (92%) n.s.
Negative/very
negative
0  1 (3%)
Neither positive or
negative
1 (3%) 2 (5%)
Rate your perception undergoing a caesarean section
Very positive 29 (76%) 26 (67%) n.s.ll data are shown as mean ± SD (range) (Student’s t-test, p ≤ 0.05 was considered
igniﬁcant).
.4. Telephone interview at ten days
Women  in the OXY group reported pain to be less of an obstacle
han women in the IVM/codeine group (79% vs. 51%). On postopera-
ive day 10, analgesics requirements were low and similar between
roups (Table 6).
.5. Safety variables
Maternal: There were two SSIs reported in each group. Three
omen in the OXY group reported adverse effects (0–24 h) vs. 15
omen in the IVM/codeine group (p = 0.007). In the OXY group
hree women felt dizziness when receiving i.v. injections of OXY.
n the IVM/codeine group the following symptoms were reported:
izziness (n = 9), nausea (n = 4), being tired (n = 1) and itching (n = 4).
Neonates: Apgar scores and umbilical cord pH were normal in
ll but three newborns.
These three newborns (two in the OXY and one in the IVM group)
ad acidosis (pH < 7.20) and were admitted to the NICU already
t the NACS baseline assessment. All three developed pulmonary
daptation syndrome (PAS). One newborn from the IVM group was
dmitted to the neonatal ward when 24 h old, also due to PAS. For all
others, treatment continued according to plan. No newborns with
igns of opioid exposure were identiﬁed. No signiﬁcant difference
n weight loss was recorded (Table 7).
.6. Patient global impression (PGI)
In the OXY group, 16/19 women with previous CS experience,
udged the present occasion to be less painful, while three judged
t as similar. In the IVM/codeine group, 11/20 women  with previ-
us CS judged pain as less, eight judged it as similar and one as
orse this time. Ten women (four in the OXY group and six in the
VM/codeine group) reported unsatisfactory pain relief. Despite this
ll women told that they gained support for their reported need for
ain relief.Positive 9 (24%) 13 (33%)
Numbers and (%) (Chi2 test, p ≤ 0.05 was considered signiﬁcant).
3.7. Nursing aspects
Total time (min) required for rescue treatment during the
ﬁrst 24 h was signiﬁcantly (p = 0.001) shorter in the OXY group
(20.7 ± 19.4) than in the IVM/codeine group (66.4 ± 38.7). Also the
number of rescue medications was  signiﬁcantly lower (p = 0.047)
in the OXY group (4.3 ± 3.6) than in the IVM/codeine group
(8.4 ± 11.7).
4. Discussion
The present study results demonstrate that a postoperative
treatment regimen using an oral formulation of a potent opioid
(OXY) was  more effective in reducing both pain and as opioid
requirement during the postoperative period after CS, when com-
pared with our standard of care, IVM and oral codeine, both as
adjunct to paracetamol + ibuprofen. Although pain at rest was lower
in the OXY group during the ﬁrst 6 h no signiﬁcant difference
was seen over the whole 0–24 h period and neither did opioid
consumption differ between groups. It is reasonable to expect
that these observations are due to the fact that a higher dose
of opioid was  administered to the OXY patients than to the IVM
patients immediately after surgery, but that all patients got an
adequate dose when asking for medication, which is consistent
with the fact that total opioid consumption was  almost identi-
cal. However, during the following days, lower pain intensity as
well as lower opioid requirement was demonstrated in the OXY
group.
Incisional pain is shown to be most intense during the ﬁrst 24 h
after surgery, while deep visceral pain is of longer duration. Further
Lenz and coworkers suggest OXY as more potent in visceral pain
than morphine, which may  contribute to the differences observed
[20].
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Table  7
Neonatal variables.
Baseline values
(before
intervention)
Neonatal outcome with
mothers in the OXY
group
(n = 38)
Neonatal outcome with
mothers in the
IVM/codeine group
(n  = 39)
Apgar score (median and range)
1 min  9 (6–10) 9 (7–10)
5  min  10 (8–10) 10 (8–10)
10  min 10 (8–10) 10 (8–10)
Umbilical cord
blood pH
(mean ± SD)
7.32 ± 0.62a 7.32 ± 0.06b
Birth weight
(mean ± SD)
3561 ± 387 3559 ± 370
NACSc (mean ± SD)
<60 min, OXY
n  = 38, IVM
n = 39
35.8 ± 2.6 35.7 ± 3.2
Neonatal care
admission (n)
2 2
NACSc (mean ± SD)
24 h, OXY
n = 36, IVM
n = 38
37.2 ± 1.7 37.2 ± 1.8
48  h, OXY
n = 35,
IVM/codeine
n = 38
Missing OXY
n = 1
37.5 ± 1.7 37.8 ± 1.6
Number of
neonates
decreasing >10%
in weight (n)
5 10
Additional feeding (n and %)
No 28 (74%) 23 (59%)
Yes 10 (26%) 16 (41%)
a Two newborns had acidosis (both with pH 7.11) and where admitted to NICU.
b One newborn had acidosis (pH 7.18) and was admitted to NICU. All three devel-
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a standardized postoperative treatment with oral OXY after CSped PAS.
c NACS – Neurological Adaptive Capacity Sore.
Both frequency and intensity of breakthrough pain (0–24 h)
ere lower in the OXY than in the IVM/codeine group. The
harmacokinetic proﬁle of slow release OXY (OxyContin) ensures
hat there are no sudden dips in drug exposure and thereby reduces
he risk of break-through pain. The lower total need for opioids,
ess frequent need for rescue medication, shorter total time for
rug administration and less opioid related adverse effects in the
others of the OXY group further demonstrate the advantages of
his protocol. There is conﬂicting data regarding the comparison
f adverse effects between OXY and morphine [14,20] but several
tudies suggest a better tolerability of OXY at equipotent doses
21–24].
In the present study the median duration of OXY or codeine
ntake was the same across groups. OXY was given up to ﬁve days
fter surgery, with doses days four and ﬁve of maximum 20 mg,
imiting the risk for signiﬁcant inﬂuence on the neonate. Due to
he interindividual differences in bioactivation of codeine the total
pioid exposure of the neonate in the group receiving IVM/codeine
an be expected to vary even more than what has been suggested
or OXY [17].
There are some limitations with the present study. First, it can
e considered a weakness that PCA morphine was  not used as com-
arator. However, the objective of the study was not to assess
he analgesic efﬁcacy of oxycodone, but to compare two  alterna-
ive low tech treatment analgesic regimens in order to optimize
he effectiveness of postoperative care after CS. PCA has neverurnal of Pain 7 (2015) 17–24 23
been introduced as routine treatment in our hospital as quick
mobilization is central and we  made the assessment that trans-
portation of a PCA devise would make the mothers less ambulatory
when taking care of their newborns. The intention with the study
was to evaluate if change of opioid could optimize pain manage-
ment. Second, the study design is not double-blind. One major
reason for this is the ethical aspect of obtaining samples of blood
from the newborn as well as breast milk during the very ﬁrst days
of lactation. We  wanted to do this in as few patients as possible,
limiting sampling to the OXY group, since there is less data avail-
able for this opioid. It is important to emphasize that mothers’ had
no opportunity to inﬂuence treatment allocation and no-one with-
drew because of this sampling. Third, pain intensity assessments
reported at regular intervals were only obtained for 48 h post-
operatively, which is when mothers and babies were discharged,
according to clinical routine. Thus, pain intensity data and anal-
gesic requirement data for days 3–5 are not as robust. Fourth, we
did not do any CYP2D6 pharmacogenomics analyses, and there-
fore some women  in the IVM/codeine group might have been slow
metabolizers, not responding to codeine, affecting their response to
treatment. Using a standardized conversion table for opioid calcu-
lations also contributes to some uncertainty in the ﬁnal evaluation.
No adverse effects of treatment on the newborns were observed
in either group. Based on NACS assessments no child showed any
sign of inﬂuence of the mother’s intake of opioid analgesics.
To the best of our knowledge this is the ﬁrst time OXY as pain
relief after CS has been compared to another regime with regard
not only to efﬁciency and safety of postoperative analgesia of the
mothers but also by a quantiﬁed evaluation of postnatal adaptation
in connection to breastfeeding. The NACS has been questioned as
a reliable tool, with a low test–retest reliability in detecting differ-
ences between neonatal outcomes after different types of obstetric
anaesthesia for CS [25]. However, there is a general lack of better
tools. We  considered that supervised training of only two study
raters by an expert neonatologist has optimized this tool for the
present use.
The strength of our study is that it is prospective and that there
was a high compliance among the women participating in the
study. A previous retrospective cohort study by Lam et al. reported
a higher incidence of central nervous system symptoms in breast
fed newborns by mothers treated with OXY than mothers treated
with paracetamol or codeine [26]. As pointed out in a reply to the
study by Lam, the long recall time was  a pronounced weakness of
that study [27]. Studies prospectively examining how OXY affects
the breastfed infant have been requested [28].
Seaton et al. studied maternal serum and breast milk levels after
OXY intake and transport through breast milk to the neonate was
investigated. OXY was only detected in the plasma of one neonate
(out of 41) but it was  considered possible that the levels in breast-
milk could expose the nursing neonate to more than 10% of the
therapeutic infant dose [17,29]. The need for opioids is highest dur-
ing the ﬁrst postoperative day, and decreases over time. During the
ﬁrst 24 h the normal range of breast milk transfer is only 4–6 ml/kg
infant body weight [30]. An optimized dosing of analgesics, includ-
ing opioids, during the ﬁrst 24 h after delivery, when breast milk
production is still sparse, resulting in a lower maternal require-
ment of opioid during day 2–5 post CS, may  clearly reduce the risk
of untoward exposure of the newborn, whilst the mother is opti-
mally pain relieved. The longer period to established lactation after
CS than after vaginal delivery, contributes to low child exposures,
with only small amounts of opioids being transferred to the baby.
In summary, the present prospective study demonstrates thatprovided a better pain control, with overall lower pain intensity
and lower opioid intake than a protocol using IVM/codeine, both
as components of a multimodal analgesic regime. Neither did the
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ow tech approach, supporting early ambulation, demonstrate any
afety concerns for mother and child. Further, an effective and
eliable oral standardized dosing of postoperative analgesics can
ontribute to the self-sufﬁciency of the mother in self-care and care
f the newborn.
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